The role of Budesonide-MMX in active ulcerative colitis

Once-Daily Budesonide MMX® Extended-Release Tablets Induce Remission in Patients With Mild to Moderate Ulcerative Colitis: Results From the CORE I Study

(2012) William J. Sandborn et al.   GASTROENTEROLOGY

Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management

(2012) Axel Dignass et al.   Journal of Crohns & Colitis

Efficacy of 5-Aminosalicylates in Ulcerative Colitis: Systematic Review and Meta-Analysis

(2011) Alexander C Ford et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: A double-blind, double-dummy, randomised trial

(2010) Volker Gross et al.   Journal of Crohns & Colitis

Clinical trial: Preliminary efficacy and safety study of a new Budesonide-MMX® 9mg extended-release tablets in patients with active left-sided ulcerative colitis

(2009) G.R. D'Haens et al.   Journal of Crohns & Colitis

Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis

(2008) M A Kamm et al.   GUT

Azathioprine Is Superior to Budesonide in Achieving and Maintaining Mucosal Healing and Histologic Remission in Steroid-Dependent Crohnʼs Disease

(2008) Gerassimos J. Mantzaris et al.   INFLAMMATORY BOWEL DISEASES